Napo Pharmaceuticals
San Francisco
About Napo Pharmaceuticals
Napo Pharmaceuticals, Inc. develops and commercializes proprietary pharmaceuticals for international markets. It offers Crofelemer for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS; and NP-500, a product for insulin-resistant diseases. The company also provides CRO-IBS for diarrhea-predominant IBS; CRO-HIV for AIDS-related diarrhea; CRO-ID for acute infectious diarrhea; and CRO-PED for pediatric diarrhea. It offers its products for D-IBS, HIV, acute-cholera, and pediatric markets. The company was founded in 2001 and is based in San Francisco, California. It has a subsidiary location in Mumbai, India.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $19.6M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2023)
- Website: napopharma.com
- Phone: +114153718300
Industries & Categories
Biotechnology, Collaboration, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/napo-pharmaceuticals-11890 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.